Cetera Advisors LLC increased its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 73.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 78,983 shares of the company’s stock after purchasing an additional 33,414 shares during the quarter. Cetera Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $540,000 at the end of the most recent quarter.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other hedge funds also recently modified their holdings of the stock. AdvisorNet Financial Inc grew its holdings in Teva Pharmaceutical Industries by 71.3% during the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after purchasing an additional 1,525 shares during the last quarter. First Interstate Bank purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $28,000. Motco purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $28,000. Lindbrook Capital LLC lifted its position in shares of Teva Pharmaceutical Industries by 76.6% in the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock worth $31,000 after purchasing an additional 1,935 shares during the period. Finally, Pacer Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $32,000. Institutional investors own 57.81% of the company’s stock.
Several brokerages have recently weighed in on TEVA. ValuEngine raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th. SunTrust Banks decreased their price target on shares of Teva Pharmaceutical Industries to $7.00 and set a “hold” rating on the stock in a research note on Thursday, August 8th. Raymond James cut their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Cowen set a $9.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Wednesday, August 7th. Finally, Guggenheim began coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They issued a “neutral” rating for the company. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $10.83.
Shares of Teva Pharmaceutical Industries stock opened at $10.23 on Monday. Teva Pharmaceutical Industries Ltd has a one year low of $6.07 and a one year high of $22.29. The firm has a market capitalization of $11.19 billion, a price-to-earnings ratio of 3.65, a PEG ratio of 1.10 and a beta of 1.73. The business has a 50-day simple moving average of $8.27 and a 200 day simple moving average of $8.56. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). The business had revenue of $4.26 billion for the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: What are the FAANG Stocks?